PARP inhibitors: pitfalls and promises
Mené sur 100 patients atteints d'une tumeur de stade avancé, cet essai de phase I évalue la doxe maximale tolérée et l'activité antitumorale du niraparib, un inhibiteur de PARP
Enthusiasm swelled for inhibition of poly(ADP-ribose) polymerase (PARP) as a treatment strategy in oncology when the oral inhibitor of PARP-1 and PARP-2 olaparib produced durable responses in patients with ovarian and breast cancer and BRCA mutations. A randomised phase 2 trial in patients with triple-negative breast cancer fuelled the growing excitement when it showed an improvement in overall survival when intravenous iniparib was added to standard gemcitabine and carboplatin chemotherapy...
The Lancet Oncology , commentaire, 2012